Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
NCT ID: NCT00283751
Last Updated: 2017-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
583 participants
INTERVENTIONAL
2003-03-31
2004-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00909480
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
NCT00097084
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
NCT00312104
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
NCT00104182
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
NCT00537303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
insulin detemir
insulin glargine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Oral Antidiabetic Drug treatment for at least 4 months
* Body Mass Index (BMI) less than 40 kg/m2
* HbA1c 7.5-10.0%
Exclusion Criteria
* Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months
* Proliferative retinopathy or maculopathy
* Known hypoglycaemia unawareness
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Greenbrae, California, United States
Novo Nordisk Investigational Site
La Mesa, California, United States
Novo Nordisk Investigational Site
West Palm Beach, Florida, United States
Novo Nordisk Investigational Site
Atlanta, Georgia, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Springfield, Illinois, United States
Novo Nordisk Investigational Site
Topeka, Kansas, United States
Novo Nordisk Investigational Site
Chesterfield, Missouri, United States
Novo Nordisk Investigational Site
St Louis, Missouri, United States
Novo Nordisk Investigational Site
Lincoln, Nebraska, United States
Novo Nordisk Investigational Site
Pleasantville, New Jersey, United States
Novo Nordisk Investigational Site
Cleveland, Ohio, United States
Novo Nordisk Investigational Site
Kettering, Ohio, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Mt. Pleasant, South Carolina, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
Warrenton, Virginia, United States
Novo Nordisk Investigational Site
Seattle, Washington, United States
Novo Nordisk Investigational Site
Ebreichsdorf, , Austria
Novo Nordisk Investigational Site
Gratwein, , Austria
Novo Nordisk Investigational Site
Graz, , Austria
Novo Nordisk Investigational Site
Neunkirchen, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Wolfsberg, , Austria
Novo Nordisk Investigational Site
Bonheiden, , Belgium
Novo Nordisk Investigational Site
Brussels, , Belgium
Novo Nordisk Investigational Site
Edegem, , Belgium
Novo Nordisk Investigational Site
Ghent, , Belgium
Novo Nordisk Investigational Site
Leuven, , Belgium
Novo Nordisk Investigational Site
Besançon, , France
Novo Nordisk Investigational Site
Bondy, , France
Novo Nordisk Investigational Site
Grenoble, , France
Novo Nordisk Investigational Site
La Rochelle, , France
Novo Nordisk Investigational Site
Lyon, , France
Novo Nordisk Investigational Site
Nantes, , France
Novo Nordisk Investigational Site
Narbonne, , France
Novo Nordisk Investigational Site
Nîmes, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Poitiers, , France
Novo Nordisk Investigational Site
Strasbourg, , France
Novo Nordisk Investigational Site
Toulouse, , France
Novo Nordisk Investigational Site
Bad Kreuznach, , Germany
Novo Nordisk Investigational Site
Bad Mergentheim, , Germany
Novo Nordisk Investigational Site
Bad Neuenahr-Ahrweiler, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Dresden, , Germany
Novo Nordisk Investigational Site
Flensburg, , Germany
Novo Nordisk Investigational Site
Frankfurt, , Germany
Novo Nordisk Investigational Site
Freiburg im Breisgau, , Germany
Novo Nordisk Investigational Site
Friedrichsthal, , Germany
Novo Nordisk Investigational Site
Fürth, , Germany
Novo Nordisk Investigational Site
Genthin, , Germany
Novo Nordisk Investigational Site
Giessen, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Heidelberg, , Germany
Novo Nordisk Investigational Site
Krefeld, , Germany
Novo Nordisk Investigational Site
Ludwigshafen, , Germany
Novo Nordisk Investigational Site
Marl, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Neumünster, , Germany
Novo Nordisk Investigational Site
Neuss, , Germany
Novo Nordisk Investigational Site
Nuremberg, , Germany
Novo Nordisk Investigational Site
Rehlingen-Siersburg, , Germany
Novo Nordisk Investigational Site
Saarbrücken, , Germany
Novo Nordisk Investigational Site
Saint Ingbert, , Germany
Novo Nordisk Investigational Site
Schaafheim, , Germany
Novo Nordisk Investigational Site
Schwabenheim, , Germany
Novo Nordisk Investigational Site
Schwedt, , Germany
Novo Nordisk Investigational Site
Völklingen, , Germany
Novo Nordisk Investigational Site
Würzburg, , Germany
Novo Nordisk Investigational Site
Dublin, , Ireland
Novo Nordisk Investigational Site
Dublin, , Ireland
Novo Nordisk Investigational Site
Ayr, , United Kingdom
Novo Nordisk Investigational Site
Barnsley, , United Kingdom
Novo Nordisk Investigational Site
Bolton, , United Kingdom
Novo Nordisk Investigational Site
Bradford, , United Kingdom
Novo Nordisk Investigational Site
Church Village, , United Kingdom
Novo Nordisk Investigational Site
Cosham, , United Kingdom
Novo Nordisk Investigational Site
Dundee, , United Kingdom
Novo Nordisk Investigational Site
Glasgow, , United Kingdom
Novo Nordisk Investigational Site
Harrow, , United Kingdom
Novo Nordisk Investigational Site
Leicester, , United Kingdom
Novo Nordisk Investigational Site
Leicester, , United Kingdom
Novo Nordisk Investigational Site
Livingstone, , United Kingdom
Novo Nordisk Investigational Site
London, , United Kingdom
Novo Nordisk Investigational Site
Newcastle, , United Kingdom
Novo Nordisk Investigational Site
Poole, , United Kingdom
Novo Nordisk Investigational Site
Salford, , United Kingdom
Novo Nordisk Investigational Site
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008 Mar;51(3):408-16. doi: 10.1007/s00125-007-0911-x. Epub 2008 Jan 16.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN304-1373
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.